Adhera Therapeutics Inc (ATRX) financial statements (2021 and earlier)

Company profile

Business Address P.O. BOX 2161
WAKE FOREST, NC 27588
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 040012
Cash and cash equivalents 040012
Receivables  0   1
Inventory, net of allowances, customer advances and progress billings  0    
Inventory  0    
Prepaid expense 00  0 
Other current assets     0 
Other undisclosed current assets 0000 0
Total current assets: 050013
Noncurrent Assets
Property, plant and equipment  0    
Intangible assets, net (including goodwill)  06677
Goodwill   44  
Intangible assets, net (excluding goodwill)  03277
Other noncurrent assets     0 
Total noncurrent assets:  06677
TOTAL ASSETS: 056689
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 522222
Accounts payable 101111
Accrued liabilities 111111
Employee-related liabilities     00
Taxes payable      0
Interest and dividends payable 31    
Debt 5 00  
Due to related parties 0010  
Other undisclosed current liabilities   20 (0)
Total current liabilities: 1026322
Noncurrent Liabilities
Liabilities, other than long-term debt     22
Deferred tax liabilities, net   22
Other undisclosed noncurrent liabilities     39
Total noncurrent liabilities:     512
Total liabilities: 10263714
Stockholders' equity
Stockholders' equity attributable to parent, including: (10)3030(4)
Common stock 0001  
Additional paid in capital 292985335333
Accumulated deficit (39)(26)(8)(2)(334)(338)
Other undisclosed stockholders' equity attributable to parent  0  00
Total stockholders' equity: (10)3030(4)
TOTAL LIABILITIES AND EQUITY: 056689

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 00  11
Revenue, net  11
Cost of revenue
(Cost of Goods and Services Sold)
 (0)(0)    
Gross profit: (0)(0)  11
Operating expenses (11)(15)(6)(1)(5)(4)
Operating loss: (11)(16)(6)(1)(4)(4)
Nonoperating income (expense)  (1)(0)(0)7(3)
Interest and debt expense (1)(1)(0)(0) 0
Income (loss) from continuing operations before equity method investments, income taxes: (12)(18)(6)(1)3(6)
Other undisclosed income (loss) from continuing operations before income taxes 0100 (0)
Income (loss) from continuing operations before income taxes: (12)(17)(6)(1)3(6)
Income tax expense   (0)(0)  
Net income (loss) attributable to parent: (12)(17)(6)(1)3(6)
Preferred stock dividends and other adjustments (2)(1)    
Other undisclosed net loss available to common stockholders, basic     (1) 
Net income (loss) available to common stockholders, diluted: (13)(18)(6)(1)3(6)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss): (12)(17)(6)(1)3(6)
Comprehensive income (loss), net of tax, attributable to parent: (12)(17)(6)(1)3(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: